Bellaterra (Barcelona), 1 December 2024. RESKIN (CI-20039), the project selected by the CaixaImpulse Innovation programme of the “la Caixa” Foundation to develop antimicrobial bioinspired membranes for skin regeneration, starts today. The project is led by Dr. Salvio Suárez-García at the Catalan Institute of Nanoscience and Nanotechnology (ICN2), and Tirecat Health takes part as linked third party.

The project
| Programme | CaixaImpulse Innovation, “la Caixa” Foundation (2024 call), phase 2 |
| Project | RESKIN: Antimicrobial bioinspired membranes for skin regeneration (CI-20039) |
| Led by | Dr. Salvio Suárez-García, ICN2 |
| Linked third party | Tirecat Health |
| Duration | December 2024 to November 2026 |
RESKIN is one of the 29 biomedical projects chosen by the “la Caixa” Foundation from more than 400 applications in its 2024 call, and one of the 11 that entered phase 2. Besides funding, the programme offers mentoring, consultancy and specialised training in technology transfer, intellectual property and fundraising, to bring research results closer to patients.
Why RESKIN
Skin wounds such as burns and chronic ulcers heal slowly and are often held back by infection, a major clinical challenge with few effective treatments. The NANOSFUN group at ICN2 has developed a family of membranes inspired by the way mussels stick to wet rocks. In earlier preclinical studies these membranes proved biocompatible, adhered to wet tissue, delivered cells to the damaged area and prevented bacterial infection thanks to their intrinsic antimicrobial activity.
RESKIN will bring these regenerative and antibacterial functions together in a single, ready-to-use membrane, focusing on two hard-to-treat lesions: burns and diabetic foot ulcers. The final aim is to prepare the device for a first study in patients.

Four milestones in two years
- M1 · Preclinical validation: validate the membrane as a medical device in a porcine model of infected skin wounds, showing that it prevents infection and speeds up healing.
- M2 · Scalability: explore production with external manufacturers under the quality standards required for medical devices.
- M3 · Regulatory pathway: define the full regulatory route as a medical device and start building the product file.
- M4 · Project ecosystem: business plan, contacts with investors, companies and clinicians, and new applications for the pipeline.
The role of Tirecat Health
Tirecat Health, the ICN2–CSIC spin-off that holds the exclusive worldwide licence of the technology (patent WO2022/258780), works side by side with ICN2 as linked third party. While the research team leads the preclinical work, the company brings the industrial, regulatory and business view: it prepares the transfer to manufacturing, drives the regulatory strategy, writes the business plan and builds the relationships with clinicians, partners and investors that will take RESKIN from the laboratory to patients.
The project runs until November 2026. We will report on its results when it ends.
RESKIN is an investigational medical device and is not available for sale.
This content reflects only the authors’ view. The “la Caixa” Foundation is not responsible for any use that may be made of the information it contains.
Follow our progress
News, milestones and calls for collaboration, first on LinkedIn.

